Risk factors for hepatitis C virus infection among blood donors in Beijing and implications for improving the pretesting donor screening process

Qiu, Yan; Shi, Ling; Wang, Yichuan; Gui, Zhilun; Zheng, Jing; Gong, Xun; Xia, Hongying; Zhang, Ping; Ness, Paul M.; Shan, Hua

doi:10.1111/j.1537-2995.2008.01673.x

Cited by 5 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of 425 patients from a single hospital population reported genotypes 1 (14%), 1a (15%), 1b (23%), 2 (9%), 3 (31%), 4 (5%), 6 (2%) and mixed (1%) (27). The results were consistent with other work conducted by a national reference laboratory (26), which also showed that genotype 3 was more prevalent in younger age cohorts (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40) year olds), indicative of transmission via IDU, and that genotype 1b was identified more frequently among patients with transfusion-acquired HCV (26).…”

Section: Genotype Distributionsupporting

confidence: 86%

“…In children, the prevalence was reported between 0.1 and 0.9% (259,273). A general increase in prevalence with age was observed: 4.49% in o 15, 2.05% in [15][16][17][18][19][20][21][22][23][24]5.10% in [25][26][27][28][29][30][31][32][33][34]8.64% in 35-44, 15% in 45-54 and 11.9% in Z55 years old in a cohort of outpatient attendees and admitted patients (250). Others reported that prevalence was highest in males aged 4 40 years (6.2%) and in females 40-49 years (5.0%) (246).…”

Section: Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

Sievert

Altraif

Razavi

et al. 2011

Liver International

495

379

View full text Add to dashboard Cite

Background: The hepatitis C pandemic has been systematically studied and characterized in North America and Europe, but this important public health problem has not received equivalent attention in other regions. Aim: The objective of this systematic review was to characterize hepatitis C virus (HCV) epidemiology in selected countries of Asia, Australia and Egypt, i.e. in a geographical area inhabited by over 40% of the global population. Methodology: Data references were identified through indexed journals and non‐indexed sources. In this work, 7770 articles were reviewed and 690 were selected based on their relevance. Results: We estimated that 49.3–64.0 million adults in Asia, Australia and Egypt are anti‐HCV positive. China alone has more HCV infections than all of Europe or the Americas. While most countries had prevalence rates from 1 to 2% we documented several with relatively high prevalence rates, including Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%). Nosocomial infection, blood transfusion (before screening) and injection drug use were identified as common risk factors in the region. Genotype 1 was common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 was found in Vietnam and other Southeast Asian countries. In India and Pakistan genotype 3 was predominant, while genotype 4 was found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. Conclusion: We recommend implementation of surveillance systems to guide effective public health policy that may lead to the eventual curtailment of the spread of this pandemic infection.

show abstract

Section: Genotype Distributionsupporting

confidence: 86%

Section: Risk Factorsmentioning

confidence: 99%

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

Sievert

Altraif

Razavi

et al. 2011

Liver International

495

379

View full text Add to dashboard Cite

show abstract

“…History of blood transfusion has consistently been reported to be associated with HCV infection among Chinese blood donors . A previous risk factor study in Beijing blood donors found that the majority (91.7%) of HCV cases had received transfusion before 1996 .…”

Section: Discussionmentioning

confidence: 39%

Risk factors for hepatitis B and C infection among blood donors in five Chinese blood centers

Huang

Guo

et al. 2014

Transfusion

Self Cite

View full text Add to dashboard Cite

show abstract

“…Few other studies also have shown an association of history of blood transfusion with an increased risk of polymerase chain reaction (PCR) positivity or confirmed HCV cases. [91011]…”

Section: Discussionmentioning

confidence: 99%

Serial follow-up of repeat voluntary blood donors reactive for anti-HCV ELISA

Choudhury¹,

Tulsiani²,

Desai³

et al. 2011

Asian J Transfus Sci

View full text Add to dashboard Cite

Background:Voluntary non-remunerated repeat blood donors are perceived to be safer than the first time blood donors. This study was planned for follow-up of previous hepatitis C virus (HCV) test results of anti-HCV enzyme-linked immunosorbent assay (ELISA) reactive repeat blood donors. The aim was to suggest a protocol for re-entry of the blood donors who are confirmed HCV negative by nucleic acid test (NAT) and recombinant immunoblot assay (RIBA). A group of repeat voluntary donors were followed retrospectively who became reactive on a cross sectional study and showed HCV reactivity while donating blood regularly.Material and Methods:A total of 51,023 voluntary non remunerated blood donors were screened for anti-HCV ELISA routinely. If anybody showed positivity, they were tested by two ELISA kits (screening and confirmatory) and then confirmed infection status by NAT and or RIBA. The previous HCV test results of repeat donors reactive by anti-HCV ELISA were looked back from the records. Data of donors who were repeat reactive with single ELISA kit (in the present study) were analyzed separately from those reactive with two ELISA kits (in the present study).Results:In this study, 140 (0.27%) donors who were reactive by anti HCV ELISA were included. Out of them, 35 were repeat voluntary donors and 16 (11.43%) were reactive with single ELISA kit. All 16 donors were reactive by single ELISA kit occasionally in previous donations. Their present ELISA positive donations were negative for HCV NAT and RIBA. A total of 19 (13.57%) donors were reactive with two ELISA kits. In their previous donations, the donors who were reactive even once with two ELISA kits were consistently reactive by the same two ELISA kits in their next donations also.Conclusion:Donor sample reactive by only single ELISA kit may not be considered as infectious for disposal as they were negative by NAT and or RIBA. One time ELISA positivity was found probably due to ELISA kit specificity and sensitivity. Donors reactive with two ELISA kit should be discarded as there is a high positivity with NAT/ RIBA. However, donors reactive by two ELISA kits and negative by NAT and RIBA should be followed up and may not be deferred permanently.

show abstract

Risk factors for hepatitis C virus infection among blood donors in Beijing and implications for improving the pretesting donor screening process

Abstract: Histories of blood transfusion before 1995, plasma donation, previous hepatitis infection, or elevated ALT were risk factors for HCV infection among blood donors in Beijing.

Cited by 5 publications

References 15 publications

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

Risk factors for hepatitis B and C infection among blood donors in five Chinese blood centers

Serial follow-up of repeat voluntary blood donors reactive for anti-HCV ELISA

Contact Info

Product

Resources

About